BHC(SH:600721) Xin Lang Cai Jing·2025-11-13 02:07Core Viewpoint - Baohua Pharmaceutical has shown a significant increase in stock price and trading activity, indicating positive market sentiment and potential growth opportunities in the pharmaceutical sector [1][2]. Company Overview - Baohua Pharmaceutical, established on June 21, 1996, and listed on June 26, 1996, is located in Urumqi, Xinjiang. The company specializes in early drug discovery, CMC development, clinical trials, registration, and various pharmaceutical services [2]. - The company's revenue composition includes 49.39% from clinical trials, 42.67% from drug research and consistency evaluation, 6.69% from leasing and property services, and 0.94% from other income [2]. - As of September 30, the number of shareholders increased by 10.56% to 33,200, with an average of 11,584 circulating shares per person, a decrease of 9.49% [2]. Financial Performance - For the period from January to September 2025, Baohua Pharmaceutical achieved a revenue of 299 million yuan, representing a year-on-year growth of 2.74%. The net profit attributable to the parent company was 32.67 million yuan, reflecting a year-on-year increase of 36.41% [2]. - The company has cumulatively distributed 6.1275 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Stock Performance - As of November 13, Baohua Pharmaceutical's stock price increased by 41.88% year-to-date, with a 3.77% rise in the last five trading days and a 15.86% increase over the past 60 days [1]. - The stock's trading volume showed a net inflow of 2.1175 million yuan from main funds, with significant buying activity from large orders [1].